Why Lurasidone Matters
Lurasidone has a specific and useful niche: it is the second-generation antipsychotic you reach for when metabolic safety matters and the target is bipolar depression rather than mania. It is one of a short list of agents FDA-approved for bipolar I depression, and of those it is arguably the most metabolically clean, with minimal weight gain, nearly flat lipids and glucose, negligible QT effect, and low prolactin. In a class defined by weight gain and dyslipidemia, that profile is its whole reason for existing.
The trade-offs are just as specific. Lurasidone has no antimanic evidence. It was never tested in acute mania and should not be used as bipolar monotherapy for a patient who cycles into mania without mood-stabilizer coverage. Its akathisia burden is real, and it is the leading tolerability reason people stop the drug. It also has an absorption quirk: it must be taken with a meal of at least 350 calories, or the patient absorbs roughly half the dose or less. Ziprasidone also has to be taken with food; lurasidone is the one whose label sets a specific calorie floor. More than a few "non-responders" are simply people who took their tablet on an empty stomach.
Lurasidone is an excellent choice for bipolar depression and a reasonable one for schizophrenia in the metabolically vulnerable patient, provided you take three things seriously: the food requirement, the akathisia, and the CYP3A4 interactions. If you get those right, it is a well-tolerated, once-daily, cognitively gentle antipsychotic. Otherwise you end up with a patient who "failed" a drug they never absorbed, or who quit within two weeks from restlessness you could have prevented.
It is now generic, roughly $10 to $20 a month, down from about $1,000 a month at launch, so the cost barrier that once kept it in prior-authorization limbo is gone. That counts in its favor too.
Part 1: Indications
FDA-Approved Uses
- Schizophrenia (adults, 2010; adolescents 13 to 17, later extension)
- Bipolar I depression (2013), both as monotherapy and as adjunct to lithium or valproate (pediatric bipolar depression, ages 10 to 17, subsequently approved)
There is no indication for acute mania and no maintenance/prophylaxis indication; a brief bipolar maintenance trial did not succeed at 6 months. Lurasidone is a depression-and-psychosis drug, not a mania drug.
The Evidence-Based Clinical Uses
Bipolar I depression: the sweet spot. A 6-week placebo-controlled monotherapy trial with two dose arms showed response around 51 to 53% vs about 30% placebo, with remission around 40 to 42% vs about 25%. As adjunct to lithium or valproate, response was about 57% vs 42% and remission about 50% vs 35%. The efficacy is solid, and it comes without the metabolic penalty of quetiapine or the olanzapine-fluoxetine combination.
For bipolar depression, there is no dose-response benefit. Low dose (20 to 60 mg) and high dose (80 to 120 mg) performed almost identically (53% vs 51% response). Higher doses add akathisia, insomnia, and agitation without adding antidepressant effect. Start low and stay low unless you have a specific reason to climb.
Schizophrenia. Solidly effective: 4 of 5 placebo-controlled pivotal trials were positive, and a network meta-analysis of 10 RCTs confirmed that all doses except 20 mg beat placebo. Here, unlike in depression, efficacy is dose-dependent: 80 mg/day is roughly the "effective dose 50," and 160 mg/day outperforms all lower doses on PANSS. It is a mid-range-efficacy antipsychotic (not clozapine, not olanzapine for refractory positive symptoms), chosen largely for its tolerability rather than raw potency.
Bipolar depression with cognitive complaints. Lurasidone is the antipsychotic most often cited for a possible pro-cognitive signal, tied to its strong 5-HT7 antagonism. Be honest about the evidence: the human cognition data are modest, partly sponsor-driven, and in a head-to-head against ziprasidone showed no clear advantage. The "cognition" endpoint in the schizophrenia trial was a PANSS subscale (thought organization), not formal neuropsychological testing. Reasonable to prefer it when cognition is a stated concern; don't oversell it.
Off-label, defensible: adjunctive treatment of unipolar major depression has no dedicated RCTs. Still, lurasidone clearly works in bipolar depression, and several antipsychotics (aripiprazole, brexpiprazole, cariprazine, quetiapine) share a class antidepressant-augmentation effect (NNT about 4), so it is a logical, if not yet data-based, augmentation choice, particularly for patients who cannot tolerate aripiprazole or quetiapine. Also reasonable: major depression with mixed features, and the depressed phase of schizoaffective disorder.
Worst Uses
- Acute mania: never tested; no antimanic evidence. Do not treat mania with lurasidone.
- Bipolar I monotherapy in a patient who needs mania protection: pair it with lithium/valproate, or choose a different agent.
- Bipolar maintenance monotherapy: the preventive data are not there yet.
Think of lurasidone as the metabolically clean bipolar-depression antipsychotic that also treats schizophrenia. If the clinical problem is mania or long-term mood stabilization, lurasidone is the wrong tool: reach for lithium, valproate, or an agent with mania and maintenance data.
Part 2: Before You Start: Workup and Candidacy
Lurasidone's baseline workup is the standard second-generation-antipsychotic metabolic panel, lighter than lithium's, because there is no narrow therapeutic window and no serum level to chase.
Baseline Assessment
| Item | Why |
|---|---|
| Weight, height, BMI, waist circumference | Anchor the metabolic monitoring; lurasidone is favorable but not zero-risk |
| Blood pressure (including orthostatics) | Alpha-1 antagonism drives orthostatic hypotension, especially early |
| Fasting glucose or HbA1c | Class metabolic baseline |
| Fasting lipid panel | Class metabolic baseline |
| CBC | General precaution (class monitoring for rare blood dyscrasias) |
| Pregnancy test | In any patient of childbearing potential |
| Review CYP3A4 med list | The single most important pre-start check for this drug (see Part 7) |
| AIMS exam | Baseline abnormal-movement screen before any dopamine blocker |
| ECG | Not routine; obtain if cardiac history or QT-risk co-meds. Lurasidone's own QT effect is negligible (~1.5 ms) |
Who Is a Poor Candidate?
- Anyone on a strong CYP3A4 inhibitor or inducer (see Part 7): these are contraindications, not cautions
- Patients who cannot or will not reliably eat with the dose: the food requirement is non-negotiable for absorption
- Patients whose target syndrome is mania or who need maintenance mood stabilization without added coverage
- History of severe, treatment-limiting akathisia on prior high-akathisia agents (aripiprazole, ziprasidone): relative caution
- Moderate to severe renal or hepatic impairment: usable, but cap the dose (Part 8)
Before you write the prescription, ask two questions out loud: "What do you usually eat at dinner?" and "Show me your current medication and supplement list, including anything from other doctors." The first predicts whether the drug will work; the second predicts whether it will be safe. Grapefruit juice and St. John's wort are the two patients forget to mention.
Part 3: How to Start and Dose
| Parameter | Value |
|---|---|
| Formulation | Tablets 20 / 40 / 60 / 80 / 120 mg (oral only; no LAI) |
| Food rule | Take with ≥350 calories — fasting cuts absorption 2–3× |
| Bipolar depression | Start 20 mg → 20–80 mg (max 120) |
| Schizophrenia | Start 40 mg → 80–160 mg |
| FDA maximum | 160 mg/day (schizophrenia); 120 mg/day (bipolar depression) |
| CYP3A4 | Contraindicated with strong 3A4 inhibitors (ketoconazole) and strong inducers (rifampin); moderate inhibitor (diltiazem, verapamil) → start 20, max 80; avoid grapefruit |
| Renal (CrCl <50) | Start 20 mg, max 80 mg/day |
| Hepatic | Moderate (Child-Pugh B): max 80; severe (C): max 40 |
| Pediatric | Schizophrenia 13–17; bipolar depression 10–17 |
| Boxed warning | Elderly dementia-psychosis mortality (class); notably metabolically clean |
Formulations
- Oral tablets only: 20, 40, 60, 80, 120 mg (the 60 mg was added post-launch)
- No IM, no long-acting injectable, no sublingual. It is a once-daily oral drug and nothing else.
The Food Rule
This is the most important sentence in this guide: Lurasidone must be taken with food containing at least 350 calories. Fasting reduces absorption dramatically, since food roughly doubles to triples serum concentration. The composition matters less than the caloric floor; about 350 kcal is the validated threshold. The dose does not need to be taken at dinner specifically, but it must be within about 30 minutes of a substantial meal or snack.
The commonest cause of "lurasidone doesn't work" is an empty stomach. Pin the dose to the patient's most reliable meal, usually dinner, and say it every visit: "With food. A real meal or a substantial snack, at least 350 calories. Not a cracker, not a black coffee." One more caution from practice: absorption is variable enough that a rare patient underabsorbs even with a meal. If someone is adherent, eating properly, and getting no effect at an adequate dose, that idiosyncrasy, not non-adherence, may be the answer.
Starting Dose and Titration
Bipolar depression (monotherapy or adjunct):
- Start: 20 mg once daily with food.
- Titrate as needed toward 20 to 80 mg/day; the usual effective range sits at the low end.
- Maximum 120 mg/day, but remember: no added antidepressant benefit above about 80 mg; higher doses mostly add akathisia and activation.
- Onset of antidepressant effect is often visible within 1 to 2 weeks.
Schizophrenia:
- Start: 40 mg once daily with food (no titration required to reach a therapeutic dose).
- Target 80 to 120 mg/day; maximum 160 mg/day.
- Here efficacy is dose-dependent: 80 mg is a common effective dose, 160 mg outperforms lower doses for refractory positive symptoms, at the cost of more akathisia, insomnia, fatigue, and agitation.
Off-label unipolar augmentation: start 20 mg, step to 40 mg; if no signal at 40 mg, move on rather than pushing higher.
Timing
Because sedation is common, evening dosing with the evening meal is the default: it converts a side effect (somnolence) into a benefit (sleep) and reliably pairs the dose with a real meal. If a patient is activated or insomniac on it, which is unusual for this drug but can happen at higher doses, morning dosing with breakfast is the alternative, again only if that breakfast is at least 350 kcal.
There is no serum level to monitor and no titration to a blood target. Dose to clinical response and tolerability.
For bipolar depression, "start 20 with dinner, reassess in two weeks, go to 40 if partial response" handles the large majority of patients. Resist the reflex to climb toward 80 to 120 just because you can: you will trade tolerability for nothing.
Dose Adjustments and Special Populations
- CYP3A4 (key): lurasidone is primarily CYP3A4-metabolized. It is contraindicated with strong 3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) and strong 3A4 inducers (rifampin, carbamazepine, St. John's wort). With a moderate 3A4 inhibitor (diltiazem, verapamil, erythromycin, fluconazole), start at 20 mg and cap at 80 mg/day; a moderate inducer may require a dose increase. Grapefruit and grapefruit juice are not contraindicated, but the label says to avoid them.
- Renal impairment: for moderate-to-severe impairment (CrCl <50 mL/min), start at 20 mg and cap at 80 mg/day.
- Hepatic impairment: moderate (Child-Pugh B), cap at 80 mg/day; severe (Child-Pugh C), cap at 40 mg/day.
- Geriatric: no specific dose change; the class boxed warning applies.
- Pediatric: schizophrenia approved 13–17; bipolar depression approved 10–17 (start 20 mg, range 20–80).
Stopping and Switching
- Discontinuation: taper to reduce the risk of relapse; its low metabolic burden makes lurasidone a common switch target from more metabolically active atypicals.
Part 4: Monitoring
Monitoring lurasidone means watching the metabolic panel and looking for movement disorders. Unlike lithium, there are no levels to chase.
| Timepoint | What to check |
|---|---|
| Baseline | Weight/BMI/waist, BP + orthostatics, fasting glucose/HbA1c, lipids, CBC, AIMS |
| ~2 to 4 weeks (post-titration) | Weight, akathisia/EPS check (ask and observe), orthostatic symptoms; repeat glucose/lipids if baseline abnormal |
| ~3 to 4 months | Weight, fasting glucose, lipids, AIMS |
| Annually thereafter (if stable) | Weight, glucose/HbA1c, lipids, AIMS |
| Every ~6 months | If weight is trending up or metabolic labs are drifting |
Movement disorders: perform an AIMS at baseline, then at least every 6 to 12 months (every 6 months is prudent in higher-risk patients). Ask about restlessness/inner tension at every early visit: akathisia is frequently missed because patients describe it as anxiety or agitation, and it is the leading tolerability reason people quit lurasidone.
Prolactin: routine measurement is not required. Increases are small (about 2 to 7 ng/mL, dose-related) and usually not clinically meaningful; check only if symptomatic (galactorrhea, menstrual change, sexual dysfunction).
ECG: not routine. Lurasidone's QT effect is negligible (mean about 1.5 ms; no patient with more than a 50 ms increase in trials, vs about 10 ms for ziprasidone). Obtain one only for cardiac history, QT-prolonging co-medications, or dosing above the approved range.
Part 5: Side Effects and How to Manage Them
As with the rest of the class, lurasidone's side effects are mostly dose-dependent, mostly early, and mostly manageable. Akathisia is the one that ends treatment, so pursue it actively rather than waiting for the patient to volunteer it.
Akathisia and EPS: the defining tolerability issue
This is lurasidone's Achilles' heel. From pooled trials: akathisia about 13% (vs 3% placebo); other EPS about 14% (vs 6%). It is dose-dependent and rises sharply above 40 mg. Reassuringly, dystonia (about 3%) and parkinsonism (about 4%) are lower than with risperidone.
Management, in order:
- Lower the dose: often the cleanest fix, and for bipolar depression you lose no efficacy doing it.
- Slow the titration if you were climbing.
- Propranolol 20 to 40 mg BID to TID: first-line pharmacologic treatment for akathisia; usually more effective than anticholinergics.
- Benzodiazepine (lorazepam 0.5 to 1 mg or clonazepam 0.5 mg) as adjunct/PRN.
- For parkinsonism/dystonia specifically, an anticholinergic (benztropine) is appropriate; note it does not treat akathisia well.
Do not confuse akathisia with worsening anxiety or agitation: the treatments diverge (you'd lower lurasidone for akathisia but might raise an antidepressant for anxiety). What gives it away: akathisia is a motor restlessness, an inability to sit still, often worse in the legs, out of proportion to the patient's stated mood. Ask specifically: "Do you feel like you have to keep moving your legs or get up and pace?" Catch it early and it's a dose adjustment; miss it and it's a discontinuation.
Sedation / Somnolence
Common: about 17% vs 7% placebo, dose-dependent (about 6% at 20 mg rising to about 22% at 120 mg). It occurs despite negligible antihistamine activity and is likely 5-HT7-mediated. More sedating than aripiprazole, less than quetiapine.
Management: dose in the evening; usually tolerable and often useful for the sleep-disrupted depressed patient. Lower the dose if daytime sedation persists.
Nausea / GI
About 10% vs 5% placebo, typically early. Conveniently, the mandatory food rule already mitigates it: taking the dose with a full meal reduces nausea. Ginger or a short course of an antiemetic covers the rest; nausea usually settles within days to a couple of weeks.
Insomnia / Activation
About 10% vs 8% placebo, more prominent at higher doses (120 to 160 mg), where anxiety, agitation, and fatigue also cluster. If activation appears, it usually means you've climbed too high: come back down.
Orthostatic Hypotension / Dizziness
From alpha-1 antagonism; usually early and mild. It was uncommon in the trials: orthostatic hypotension was reported in about 0.3% on lurasidone against 0.1% on placebo.
Management: rise slowly, hydrate, check standing BP early in treatment; slow titration and evening dosing help. Rarely dose-limiting.
Metabolic: the reason to choose this drug
This is lurasidone's main advantage:
- Weight: minimal, about half the incidence of clinically significant gain vs risperidone (about 7% vs about 14%); a 1-year open-label study showed a mean loss of about 3 lbs. A modest weight-gain signal appears above 40 mg.
- Lipids: no significant increase vs placebo.
- Glucose/HbA1c: nonsignificant changes.
Still, monitor: favorable is not immune, and individual patients gain.
Management of weight gain (when it occurs):
- Early dietary counseling (simple, concrete: roughly a quarter less on the plate).
- Metformin (e.g., 500 mg BID, titrated) for antipsychotic-associated gain.
- Fish oil, about 4 g/day if triglycerides climb above 150.
- Home weight self-monitoring to catch trends early.
Prolactin / Sexual
Small, usually subclinical prolactin rises; sexual dysfunction is less prominent than with risperidone/paliperidone. Manage symptomatically if it appears.
Class Effects to Keep in View
- Tardive dyskinesia: a class risk of any dopamine blocker, though second-generation agents carry roughly half the TD risk of typicals (annualized incidence about 2.6% against 6.5% across head-to-head trials). AIMS surveillance is how you catch it early. Lurasidone's own EPS burden is real, but TD is a long-term, cumulative risk: watch for it over years.
- Neuroleptic malignant syndrome: rare but life-threatening (see Part 6).
Part 6: Toxicity and Boxed Warnings
Lurasidone has no narrow therapeutic window and no level-driven toxicity syndrome. The safety concerns are the class boxed warnings plus NMS.
- Increased mortality in elderly patients with dementia-related psychosis. All antipsychotics carry this. Relative risk about 1.6 to 1.7 (deaths from cardiovascular events and pneumonia), NNH about 50 to 100 over about 10 weeks. Lurasidone is not approved for dementia-related psychosis. If antipsychotic use is unavoidable in that population, use the lowest dose for the shortest time with informed consent and close monitoring.
- Increased suicidality in children, adolescents, and young adults with major depressive disorder and other psychiatric conditions (the class antidepressant/CNS warning): monitor for worsening and emergent suicidality, especially early and after dose changes, in patients under about 25.
Neuroleptic Malignant Syndrome (NMS)
Rare but potentially fatal: fever, rigidity, altered mental status, autonomic instability (labile BP, tachycardia, diaphoresis), often with elevated CPK.
Management: stop the antipsychotic immediately; supportive care (cooling, hydration, monitoring); dantrolene and/or bromocriptine in severe cases. This is an emergency.
Overdose
There is no specific antidote. Lurasidone overdose is generally managed supportively: airway/cardiac monitoring, symptomatic treatment (anticonvulsant for seizure, cooling for hyperthermia). Its clean QT and metabolic profile make isolated overdose comparatively less dangerous than some older agents, but co-ingestants and CYP3A4-mediated level elevations complicate the picture. Treat in an emergency setting.
Other Class Cautions
- Seizure threshold: dopamine blockade modestly lowers it; caution with seizure history.
- Metabolic emergencies (DKA, severe hyperglycemia): a class concern, though low-probability with lurasidone's flat glucose profile.
Part 7: Drug Interactions
Lurasidone is metabolized principally by CYP3A4, and its levels swing dramatically with 3A4 inhibitors and inducers. Have this interaction profile memorized before you prescribe, because the extremes are outright contraindications.
| Category | Agents | Effect | Action |
|---|---|---|---|
| Strong CYP3A4 inhibitors | Ketoconazole (the worst actor, ~7x increase), itraconazole, voriconazole, clarithromycin, ritonavir and other protease inhibitors, boceprevir, nefazodone | CONTRAINDICATED | Levels can rise about 7-fold. Do not co-prescribe. If one is unavoidable, lurasidone should be stopped. |
| Strong CYP3A4 inducers | Rifampin (~85% reduction), carbamazepine (a common bipolar mood stabilizer, and the sneaky one), phenytoin, St. John's wort | CONTRAINDICATED | Levels fall about 85%. At these reductions the drug is effectively non-functional: don't combine. |
| Moderate CYP3A4 inhibitors | Diltiazem, erythromycin, fluconazole, verapamil, atazanavir; grapefruit and grapefruit juice, which the label says to avoid | MODERATE | Levels roughly double. Start low (20 mg) and do not exceed 80 mg/day. |
| Moderate CYP3A4 inducers | Bosentan, efavirenz, etravirine, modafinil, nafcillin | MODERATE | Reduce lurasidone levels meaningfully; you may need to increase the dose and watch for lost efficacy. |
Food belongs on the interaction list because it behaves like a pharmacokinetic interaction: taking lurasidone without at least 350 kcal of food roughly halves, or worse, its exposure. Empty-stomach dosing is a de facto underdose.
Two questions prevent nearly every serious lurasidone interaction: "Are you on any antifungals, certain antibiotics, HIV meds, or seizure meds?" and "Do you drink grapefruit juice or take St. John's wort?" Carbamazepine is the sneaky one: a bipolar patient may arrive already on it, and it will gut your lurasidone levels. Check the med list against the 3A4 lists every time you start the drug or a patient adds a new prescription.
Part 8: Special Populations
Pregnancy
Lurasidone is a second-generation antipsychotic; human pregnancy data are limited (the pre-2015 label carried "Category B", a grade that reflected the absence of an animal teratogenicity signal rather than any human safety data). The general principles for antipsychotics in pregnancy apply:
- Untreated maternal illness carries its own substantial risk: relapse of bipolar depression or psychosis in pregnancy is dangerous to mother and fetus. Continuing an effective, well-tolerated agent is often the right call.
- Third-trimester exposure to antipsychotics carries a class-label warning for neonatal extrapyramidal symptoms and/or withdrawal (agitation, feeding difficulty, respiratory distress, hyper- or hypotonia, tremor), usually self-limited. Coordinate delivery planning and neonatal monitoring.
- Lurasidone's metabolic neutrality is a relative advantage over olanzapine/quetiapine (no added gestational-diabetes/weight burden).
Individualize; involve the patient in a documented risk-benefit discussion and coordinate with obstetrics. Consider enrollment in the National Pregnancy Registry for Psychiatric Medications.
Lactation
Lurasidone breast-milk data are minimal. Most atypicals appear in breast milk in small amounts; olanzapine, quetiapine, and risperidone have more reassuring lactation records. If a mother chooses to breastfeed on lurasidone, monitor the infant for sedation, poor feeding, and irritability, in coordination with pediatrics.
Elderly
- No dose adjustment required for age alone (a convenience compared with some atypicals).
- But watch orthostatic hypotension (fall risk) with early titration, and honor the dementia-related-psychosis boxed warning: lurasidone is not for that indication.
Renal Impairment
- Mild: no adjustment.
- Moderate to severe (and ESRD): cap the dose at 50% of usual, starting dose 20 mg, maximum 80 mg/day.
Hepatic Impairment
- Mild: no adjustment.
- Moderate (Child-Pugh 7 to 9): cap the dose at 50%, starting dose 20 mg, maximum 80 mg/day.
- Severe (Child-Pugh 10 to 15): starting dose 20 mg, maximum 40 mg/day.
Children and Adolescents
- Schizophrenia: approved ages 13 to 17.
- Bipolar depression: approved ages 10 to 17.
- Efficacy and the favorable metabolic profile carry over; akathisia and the food requirement remain the practical hurdles. Honor the pediatric suicidality monitoring warning.
Part 9: Discontinuation
Lurasidone has no distinctive withdrawal syndrome and no rebound analogous to lithium's. The concern on stopping is straightforward: relapse of the underlying illness, and, as with any dopamine blocker, the theoretical possibility of withdrawal dyskinesia with very abrupt cessation.
Practical approach:
- Bipolar depression: continue 6 to 12 months after remission, then taper if discontinuing.
- Taper over about 1 to 2 months rather than stopping cold: it's smoother, and it lets you catch early relapse.
- Schizophrenia: discontinuation decisions follow standard antipsychotic-maintenance logic (many patients need indefinite treatment); abrupt cessation risks psychotic relapse.
- Monitor for symptom re-emergence throughout and have a plan to resume promptly.
Part 10: Lurasidone vs the Alternatives
| Comparison | Lurasidone Advantage | Alternative Advantage |
|---|---|---|
| vs Quetiapine (bipolar depression) | Decisively better metabolic burden and sedation; edges it on a working-memory signal in pediatric data | Larger/older evidence base; also covers mania and maintenance |
| vs Olanzapine-fluoxetine combination | Far kinder metabolically; OFC drives substantial weight and lipid gain | Comparable antidepressant efficacy in bipolar depression |
| vs Risperidone (schizophrenia) | Less weight gain (~7% vs ~14%), less dystonia and parkinsonism, less prolactin elevation | Also approved for acute mania, alone and added to lithium or valproate; available as a long-acting injectable; no food requirement |
| vs Ziprasidone | Once-daily (ziprasidone is twice-daily); even smaller QT footprint (~1.5 ms vs ~10 ms) | Comparable efficacy in head-to-head; both require food and can activate |
| vs Aripiprazole | Stronger bipolar-depression monotherapy data; possible cognitive edge | No food requirement (real-world adherence advantage); mania, maintenance, and augmentation indications; LAI available |
| vs Cariprazine | Both favorable metabolically for bipolar depression | Cariprazine additionally covers mania and maintenance; very long half-life is forgiving of missed doses |
Where lurasidone best fits: the metabolically vulnerable patient with bipolar depression (or schizophrenia) for whom weight, lipids, glucose, QT, and prolactin all need to stay quiet, and who can reliably take it with a real meal.
Where it doesn't: mania, maintenance monotherapy, patients on strong 3A4 inhibitors/inducers, and patients who won't or can't eat with the dose.
Mechanism
Lurasidone is a D2 and 5-HT2A antagonist (the standard second-generation backbone: D2 blockade for antipsychotic effect, 5-HT2A blockade to soften EPS), distinguished by four features:
- Potent 5-HT7 antagonism: its most distinctive action, and the leading candidate mechanism for its antidepressant effect and any pro-cognitive signal, and is implicated, paradoxically given minimal antihistamine activity, in its sedation.
- 5-HT1A partial agonism: a likely additional contributor to antidepressant action, a mechanism it shares in spirit with buspirone, vilazodone, and aripiprazole.
- Alpha-1 antagonism: explains the orthostatic hypotension and early dizziness.
- Negligible muscarinic (M1) and histamine (H1) activity: the reason it is metabolically clean, with no antihistaminic weight/sedation-by-H1 mechanism and no anticholinergic burden (dry mouth, constipation, cognitive fog).
In depression, the serotonergic actions (5-HT7 and 5-HT2A antagonism, 5-HT1A partial agonism) are thought to carry the antidepressant benefit, while D2 blockade is more a liability at higher doses (emotional blunting, cognitive slowing), which is why the effective antidepressant dose sits low and pushing higher adds no benefit.
Pharmacokinetics: once-daily dosing; elimination half-life on the order of about 18 hours (with an active metabolite extending the net effect); metabolized primarily by CYP3A4; absorption doubled to tripled by food (at least 350 kcal required).
The Bedside Cheat Sheet
Starting
- Bipolar depression: 20 mg once daily with food; usual range 20 to 80 mg; max 120 mg. No dose-response for depression, stay low.
- Schizophrenia: 40 mg once daily with food; target 80 to 120 mg; max 160 mg (efficacy is dose-dependent here).
- Baseline: weight/BMI/waist, BP + orthostatics, glucose/A1c, lipids, CBC, AIMS, pregnancy test, and scrub the med list for CYP3A4 drugs.
Make or break
- Food: at least 350 kcal with every dose, or absorption halves. The #1 cause of "non-response."
- Akathisia: about 13% against 3% on placebo; ask about motor restlessness at every early visit. Fix: lower dose (no efficacy lost in depression), propranolol 20 to 40 mg BID, plus or minus a benzodiazepine.
- CYP3A4: strong inhibitors (ketoconazole, clarithromycin, ritonavir, nefazodone) and strong inducers (rifampin, carbamazepine, phenytoin, St. John's wort) are contraindicated. Moderate inhibitors (diltiazem, erythromycin, fluconazole, verapamil) mean start at 20 mg and cap at 80 mg/day. Avoid grapefruit.
Monitoring
- Metabolic panel + weight at about 3 to 4 months, then annually (every 6 months if drifting). AIMS every 6 to 12 months.
- No serum level, no routine ECG (QT about 1.5 ms), and no routine prolactin.
Don't forget
- Clean: weight (often slight loss), lipids, glucose, QT, prolactin, anticholinergic effects.
- Watch: akathisia/EPS, sedation (dose in evening), early nausea (food helps), orthostasis, insomnia/activation at high doses.
- Don't use it for: acute mania, maintenance monotherapy, patients on strong 3A4 inhibitors/inducers, or patients who won't eat with it.
- Dose caps: moderate to severe renal or moderate hepatic impairment, max 80 mg/day; severe hepatic impairment, max 40 mg/day (start 20).
Lurasidone isn't the most powerful antipsychotic, and it isn't a mood stabilizer. For one specific, common problem, bipolar depression in a patient who cannot afford more metabolic risk, it is one of the best tools available: effective, once-daily, weight- and lipid-neutral, QT-quiet, prolactin-sparing, and now cheap. When it fails in practice, the cause is almost always avoidable: an empty stomach, an unrecognized akathisia, or a CYP3A4 collision. If you insist on the meal, go looking for the restlessness, and check the med list, you end up with something rare in this class, an antipsychotic patients can stay on.